Format

Send to

Choose Destination
Clin Infect Dis. 2014 Dec 1;59(11):1588-92. doi: 10.1093/cid/ciu682. Epub 2014 Sep 11.

Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.

Author information

1
Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University of Zurich, Switzerland.
2
Institute for Neuroimmunology and Clinical MS Research, Center for Molecular Neurobiology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
3
Neuroimmunology and Multiple Sclerosis Research, Department of Neurology, University of Zurich, Switzerland.
4
Department of Microbiology, Faculty of Biology, University of Barcelona, Spain.
5
Life Science Inkubator, Bonn, Germany.
6
Department of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy.
7
Department of Molecular, Cellular and Developmental Biology, University of Colorado Boulder.
8
Cytheris S.A., Issy Les Moulineaux, France.

Abstract

Progressive multifocal leukoencephalopathy is a currently untreatable infection of the brain. Here, we demonstrate in 2 patients that treatment with interleukin 7, JC polyomavirus (JCV) capsid protein VP1, and a Toll-like receptor 7 agonist used as adjuvant, was well tolerated, and showed a very favorable safety profile and unexpected efficacy that warrant further investigation.

KEYWORDS:

IL-7; JC virus; VP1; progressive multifocal leukoencephalopathy

PMID:
25214510
PMCID:
PMC4650775
DOI:
10.1093/cid/ciu682
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center